Global Medical REIT (NYSE:XRN) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Global Medical REIT (NYSE:XRN) from a hold rating to a sell rating in a research note published on Saturday.

XRN has been the topic of a number of other reports. Weiss Ratings restated a “hold (c-)” rating on shares of Global Medical REIT in a research note on Monday, April 20th. Compass Point reiterated a “neutral” rating and set a $38.00 price target (down from $50.00) on shares of Global Medical REIT in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $39.67.

Global Medical REIT Trading Up 5.2%

NYSE XRN opened at $33.97 on Friday. The company has a debt-to-equity ratio of 1.62, a quick ratio of 0.61 and a current ratio of 0.61. The firm has a market cap of $449.42 million, a PE ratio of -30.60 and a beta of 1.11. Global Medical REIT has a one year low of $29.05 and a one year high of $39.93. The firm’s fifty day moving average is $35.17 and its two-hundred day moving average is $34.40.

Global Medical REIT Announces Dividend

The firm also recently declared a monthly dividend, which will be paid on Friday, September 18th. Shareholders of record on Thursday, August 20th will be issued a $0.16 dividend. This represents a c) annualized dividend and a dividend yield of 5.7%. The ex-dividend date of this dividend is Thursday, August 20th. Global Medical REIT’s dividend payout ratio is -270.27%.

Institutional Trading of Global Medical REIT

Institutional investors and hedge funds have recently modified their holdings of the business. Heartland Advisors Inc. purchased a new stake in shares of Global Medical REIT in the third quarter valued at about $5,147,000. Peregrine Capital Management LLC purchased a new stake in shares of Global Medical REIT in the third quarter valued at about $4,785,000. Pensionfund PDN purchased a new stake in shares of Global Medical REIT in the fourth quarter valued at about $837,000. Greenland Capital Management LP purchased a new stake in shares of Global Medical REIT in the third quarter valued at about $285,000. Finally, Ballentine Partners LLC purchased a new stake in shares of Global Medical REIT in the fourth quarter valued at about $326,000. Hedge funds and other institutional investors own 57.52% of the company’s stock.

Global Medical REIT News Roundup

Here are the key news stories impacting Global Medical REIT this week:

• Positive Sentiment: Global Medical REIT announced multiple monthly dividends of $0.16 per share, reinforcing its income appeal and highlighting a dividend yield around 6%, which can support demand for the stock.
• Positive Sentiment: Compass Point reaffirmed its neutral rating but maintained a $38 price target, which is above the recent share price and suggests modest upside despite the cut from a prior target.
• Neutral Sentiment: A Seeking Alpha item highlighted the company’s Q1 2026 earnings call transcript, which may keep attention on operational performance and management guidance, but no specific new financial details were provided in the headline.
• Neutral Sentiment: Kalkine Media published a “why is the stock trending” article, indicating increased market interest in XRN, though the item itself does not identify a specific new catalyst.

Global Medical REIT Company Profile

Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.

Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.